TCM
Tang Capital Management Portfolio holdings
AUM
$1.98B
This Quarter Return
-17.36%
1 Year Return
+21.62%
3 Year Return
+290.69%
5 Year Return
+284.46%
10 Year Return
+928.34%
AUM
$712M
AUM Growth
+$712M
(-15%)
Cap. Flow
+$68.1M
Cap. Flow
% of AUM
9.56%
Top 10 Holdings %
Top 10 Hldgs %
91.51%
Holding
30
New
13
Increased
4
Reduced
2
Closed
5
Top Buys
| 1 |
Bio-Rad Laboratories Class A
BIO
|
$28M |
| 2 |
United Therapeutics
UTHR
|
$19.8M |
| 3 |
LJPC
La Jolla Pharmaceutical Company
LJPC
|
$13.2M |
| 4 |
Sangamo Therapeutics
SGMO
|
$12.9M |
| 5 |
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
|
$11.8M |
Top Sells
| 1 |
Heron Therapeutics
HRTX
|
$24.9M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
$16.9M |
| 3 |
Bristol-Myers Squibb
BMY
|
$7.18M |
| 4 |
ISEE
IVERIC bio, Inc. Common Stock
ISEE
|
$2.15M |
| 5 |
NCNA
NuCana
NCNA
|
$875K |
Sector Composition
| 1 | Healthcare | 98.74% |
| 2 | Industrials | 0.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Bristol-Myers Squibb
BMY
$96B
| – | – | -111,844 | Closed | -$7.18M |
|
|
27
Regeneron Pharmaceuticals
REGN
$61.5B
| – | – | -45,000 | Closed | -$16.9M |
|
|
ISEE
28
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
| – | – | -250,000 | Closed | -$2.15M |
|
|
EIDX
29
DELISTED
Eidos Therapeutics, Inc. Common Stock
EIDX
| – | – | -3,783 | Closed | -$217K |
|
|
BMY.RT
30
DELISTED
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
| – | – | -111,844 | Closed | -$337K |
|